We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued the first clinical trial summary in its pilot program aimed at highlighting key information from pivotal trials of newly-approved drugs. Read More
Five Manhattan doctors accepted kickbacks and bribes from Insys to prescribe its fentanyl products, according to the U.S. Attorney for the Southern District of New York. Read More
The Massachusetts Supreme Judicial Court ruled that Merck may be held liable for injuries caused by inadequate labeling for generics of its products. Read More
President Trump said that his administration will cut nationwide opioid prescriptions by one third over the next three years and increase funding for non-addictive painkiller development. Read More
He also spoke about the Prescription Interdiction and Litigation Task Force, which focuses on targeting opioid manufacturers and distributors that have contributed to the epidemic. Read More
The legislation, the Native Behavioral Health Access Improvement Act, would establish a behavioral health program to address the opioid crisis. Read More
Attorney General Jeff Sessions spoke in Lexington, Kentucky on Thursday, highlighting recently announced tools and programs geared towards fighting the U.S. opioid epidemic, including a team that will target online drug sales and a fraud detection unit. Read More
Under current quotas, 14 billion opioid doses reach the market annually — enough to prescribe a month’s worth for every adult in the country, according to co-sponsor Sen. Dick Durbin (D-Ill.). Read More
The U.K.’s Medicines and Healthcare products Regulatory Agency released new guidance on its approach to GXP data integrity and its expectations for achieving compliance. Read More